Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osivelotor for the treatment of sickle cell disease

5 Apr 2025

Abstract excerpt

INTRODUCTION: Despite advances in the treatment of sickle cell disease (SCD), an inherited disorder leading to abnormal sickle hemoglobin (HbS) polymerization, patients continue to have a shorter life expectancy comparatively to the general population. Increase in the concentration of oxygenated HbS in red blood cells (RBCs) has been considered as a novel approach to inhibit HbS polymerization and reduce RBC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood properties and coagulation
Share to Hemoglobin structure and function
Share to Hemoglobinopathies and Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40179004
DOI: 10.1080/14656566.2025.2489123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osivelotor for the treatment of sickle cell diseasePMID 40179004Read ↗

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell DiseaseSemantic proximity Read ↗

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditionsSemantic proximity Read ↗

Methemoglobin aggregation is modulated by the anti-sickling drug voxelotorSemantic proximity Read ↗

Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?Semantic proximity Read ↗

Assessing the Clinical Outcomes of Voxelotor Treatment in Patients with Sickle Cell DiseaseSemantic proximity Read ↗

Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Desidustat Oral Tablet in Sickle Cell Disease: A Phase IIa Proof-of-Concept EvaluationSemantic proximity Read ↗

Hope on the Horizon: New and Future Therapies for Sickle Cell DiseaseSemantic proximity Read ↗

Targeting sickle cell disease root-cause pathophysiology with small moleculesSemantic proximity Read ↗

Sickle Cell DiseaseSemantic proximity Read ↗

Rapid withdrawal of Voxelotor can precipitate sickle cell disease related crisisSemantic proximity Read ↗

Biomarkers and recent advances in the management and therapy of sickle cell diseaseSemantic proximity Read ↗

Sickle Cell Anemia and Antisickling Agents Then and NowSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.